A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 277 participants.

Also called NCT03242018

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 277 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03242018
Other papers using this trial's data
  • Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment Diabetes, obesity & metabolism, 2021-12 DOI, PubMed 34338408

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russia, South Africa, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03242018. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-16 (actual); primary completion 2019-05-16 (actual). Results posted on 2021-06-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Acronym
SOTA-CKD4
Condition
Type 2 Diabetes Mellitus
Condition
Chronic Kidney Disease Stage 4
Intervention (Drug)
Placebo
Intervention (Drug)
Sotagliflozin
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03242018
Content hash
948ce1d3cc8ee1d124daa2bd6b80afb101d3db7004bf9cb3c9ebc9351a91c4ab